MAP Pharmaceuticals Inc. (MAPP) announced after the bell Wednesday that its New Drug Application resubmission for LEVADEX orally inhaled migraine drug, for the potential acute treatment of migraine in adults, has been accepted for filing by the FDA.
MAP Pharmaceuticals gapped up sharply Friday and climbed in early trade, before settling into a range. The stock closed up by 2.60 at $15.42, with volume at over a 2-month high. MAP Pharmaceuticals jumped to a 2-week high and re-crossed both its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.